Search Results - "Nayak, Rahul K"

Maintenance therapy for AML after allogeneic HCT by Nayak, Rahul K., Chen, Yi-Bin

“…Allogeneic hematopoietic cell transplant (allo-HCT) for eligible patients with acute myeloid leukemia (AML) in first complete remission is a central treatment…”
Get full text

Public sector financial support for late stage discovery of new drugs in the United States: cohort study by Nayak, Rahul K, Avorn, Jerry, Kesselheim, Aaron S

“…AbstractObjectiveTo determine the extent to which late stage development of new drugs relies on support from public funding.DesignCohort study.SettingAll new…”
Get full text

340B—Where Do We Go From Here? by Kishore, Sanjay, Nayak, Rahul K, Kesselheim, Aaron S

“…This Viewpoint summarizes inefficiencies in the 340B program and provides suggestions for equitable reform that will potentially benefit patients…”
Get full text

Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress by Jazowski, Shelley A., Nayak, Rahul K., Dusetzina, Stacie B.

Get full text

The high costs of anticancer therapies in the USA: challenges, opportunities and progress by Jazowski, Shelley A., Nayak, Rahul K., Dusetzina, Stacie B.

“…The USA spent $99 billion on orally administered and clinician-administered anticancer therapies (excluding supportive care) in 2023 and spending is projected…”
Get full text

Public-sector Contributions to Novel Biologic Drugs by Nayak, Rahul K, Lee, ChangWon C, Avorn, Jerry, Kesselheim, Aaron S

Get more information

Financial toxicity in cancer care: origins, impact, and solutions by Abrams, Hannah R, Durbin, Sienna, Huang, Cher X, Johnson, Shawn F, Nayak, Rahul K, Zahner, Greg J, Peppercorn, Jeffrey

“…Abstract Financial toxicity describes the financial burden and distress that can arise for patients, and their family members, as a result of cancer treatment…”
Get full text

SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors by Nayak, Rahul K, Gerber, Drew, Zhang, Chen, Cohen, Jonathon B

“…Mantle cell lymphoma is a challenging subtype of B-cell non-Hodgkin lymphoma treat characterized by its aggressive nature and propensity for relapse or…”
Get full text

The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease? by Johnson, Micah, Kishore, Sanjay, Nayak, Rahul K., Dusetzina, Stacie B.

“…Purpose of Review Cardiovascular medications improve health and prevent early death. However, high drug prices reduce the use of these medications and strain…”
Get full text

Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act by Johnson, Micah, Nayak, Rahul K, Gilstrap, Lauren, Dusetzina, Stacie B

Get more information

The ethics of 'fail first': guidelines and practical scenarios for step therapy coverage policies by Nayak, Rahul K, Pearson, Steven D

“…In an effort to control health costs, payers are increasingly turning to step therapy (or "fail first") policies in pharmacy benefit design. These policies…”
Get full text

Pragmatic Randomized Trials Without Standard Informed Consent?: A National Survey by Nayak, Rahul K, Wendler, David, Miller, Franklin G, Kim, Scott Y H

“…Significant debate surrounds the issue of whether written consent is necessary for pragmatic randomized, controlled trials (RCTs) with low risk. To assess the…”
Get full text

Impact of race, ethnicity, and social determinants on outcomes following immune checkpoint therapy by Nayak, Rahul K, Aiello, Meili, Maldonado, Laneisha Marielis, Clark, Tarralyn Y, Buchwald, Zachary S, Chang, Andres

“…Immune checkpoint blockade (ICB) therapies are one of the greatest advances in the history of cancer care and are now commonly used in the management of many…”
Get full text

Cognitive Tests and Stool Frequency at Hospital Discharge Do Not Predict Outcomes in Hepatic Encephalopathy by Bloom, Patricia P., Miller, Samuel J., Nayak, Rahul K., Hussain, Muhammad Sarib, Arvind, Ashwini, Bay, Camden, Chung, Raymond T.

“…Hepatic encephalopathy (HE) is associated with hospital readmissions and mortality. We sought to determine whether cognitive testing and stool frequency at…”
Get full text

Cost-Related Motivations for Research—Reply by Nayak, Rahul K, Miller, Franklin G

Get full text

Is it important to disclose how treatments are selected in clinical research and clinical care? by Nayak, Rahul K., Wendler, David

“…Background: Current practice and policies maintain that it is very important to disclose to potential research subjects that their treatment will be selected…”
Get full text

Cost-Related Motivations for Conducting Research: Participants Should Be Informed by Nayak, Rahul K, Pearson, Steven D, Miller, Franklin G

“…Many groups in the US are concerned about the increasing cost of health services and have sought to reduce health care spending while maintaining the quality…”
Get full text

Public sector financial support for late stage discovery of new drugs in the United States: cohort study by Nayak, Rahul K, Avorn, Jerry, Kesselheim, Aaron S

Get full text

Public Support for Late-Stage New Drug Discovery by Nayak, Rahul K

“…Objective: To determine the role of publicly-supported research in the development of innovative new medications.Design: We examined patent data and drug…”
Get full text